Search
for
Sort by
Research 91–120 of 1000+
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Genetic alteration of cyclic adenosine 3',5'-monophosphate-dependent protein kinase subunit expression affects calcium currents and beta-endorphin release in AtT-20 clonal pituitary cells.
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Purified Vitexin Compound 1 Inhibits UVA-Induced Cellular Senescence in Human Dermal Fibroblasts by Binding Mitogen-Activated Protein Kinase 1
- ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Ornithine Decarboxylase Expression Leads to Translocation and Activation of Protein Kinase CK2 in Vivo
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Janus kinase inhibitors for alopecia areata: A narrative review
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Janus kinase inhibitors for alopecia areata
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion.
- Protein Kinase Cε, which Sensitizes Skin to Sun's UV Radiation–Induced Cutaneous Damage and Development of Squamous Cell Carcinomas, Associates with Stat3
- Protein-phosphatase inhibitors block root hair growth and alter cortical cell shape of Arabidopsis roots
- Protein Kinase C δ Overexpressing Transgenic Mice Are Resistant to Chemically but not to UV Radiation–Induced Development of Squamous Cell Carcinomas: A Possible Link to Specific Cytokines and Cyclooxygenase-2
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- A review of Janus kinase inhibitor use in scarring alopecia
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review